Skip to main content
. 2026 Mar 12;16(3):60. doi: 10.3390/clinpract16030060
Case 2a: GSM with a History of Estrogen Receptor (ER) + Breast Cancer; on Treatment with Tamoxifen.
History
of
present
illness
  • 48-year-old, postmenopausal, G2P2 female

  • Last menstrual period age 47

  • History of breast cancer diagnosed at age 45

  • Presents with vaginal dryness, discharge, dyspareunia

Past
history
  • Stage 1 ER/PR positive invasive ductal cancer diagnosed at age 45 years
    • ○
      Underwent lumpectomy and radiation therapy
    • ○
      Currently on selective estrogen receptor modulator (tamoxifen) for breast cancer recurrence risk reduction
  • Up to date on breast cancer surveillance, colon and cervical cancer screening

Medications
&
supplements
  • Tamoxifen 20 mg orally once daily

  • Levothyroxine 100 μg orally once daily

  • Multivitamin one tablet orally once daily

  • Tums 600 mg orally twice daily

Social
history
  • Alcohol 1–2 drinks (1.5 oz each) per month

  • Nonsmoker

  • No recreational drug use

  • Married, decreased sexual desire, with resulting relational strain with her 51-year-old husband

Gynecologic
examination
Mirrored exam performed with patient participation.
External genitalia
  • Labial thinning with preserved interlabial folds

  • No adhesions or white lesions

  • Mucosal pallor and decreased rugosity noted at the introitus

Speculum examination
  • Copious clear discharge present with no odor or underlying erythema

  • Decreased vaginal rugosity

  • Cervix visualized and healthy

  • Vaginal swabs obtained to rule out infectious etiology of the discharge (and results came negative for infectious vaginitis)

Bimanual examination
  • Performed with two fingers and ample lubrication

  • Positive for discomfort at the introitus as well as with deeper palpation over the pelvic floor muscles globally

  • Uterus normal size and mobile, non-tender

  • No cervical motion tenderness or adnexal masses noted